Amgen showcases its last big round of promising KRAS G12C data for sotorasib. Next up: A likely marketing campaign for a breakthrough therapy
Amgen is showing off the last, breakthrough round of data it has from the pivotal study for its KRAS G12C drug sotorasib in non-small cell lung cancer — the data they’ll be going to market with, if regulators come through with an accelerated OK soon, which is widely expected.
The data are arriving in advance of the scheduled release for the World Conference on Lung Cancer, courtesy of an embargo break on the PR for the data, which surfaced early in China. But that helps illustrate just how eagerly awaited the data are as the FDA reviews the results for a drug that currently has “breakthrough” status from late last year, putting the program on a shortcut to a near-term marketing decision.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.